Article information
Abstract
Rosacea is a chronic inflammatory skin disease appearing in the central area of the face of middleaged patients. It is characterized by flushing, permanent erythema, telangiectasia, papules, pustules, and the absence of comedones. Its underlying pathophysiologic mechanisms are not completely understood, although a number of hypotheses point to vascular abnormalities and infection by microorganisms such as Demodex folliculorum. Rosacea is classified into 4 subtypes, which determine the therapeutic approach based on skin care, topical anti-inflammatory agents, topical and oral antibiotics and retinoids, and, in some instances, light-based therapy and surgery.
Key words:
rosacea
flushing
Demodex folliculorum
metronidazole
azelaic acid
tetracyclines
retinoids
Resumen
La rosácea es una dermatosis inflamatoria crónica que asienta en el área centrofacial de pacientes de mediana edad. Se caracteriza por episodios transitorios de rubor, eritema permanente, telangiectasias, pápulas y pústulas, con ausencia de comedones. Se desconocen los mecanismos fisiopatológicos subyacentes, aunque se dispone de varias hipótesis que implican principalmente las alteraciones vasculares y la infestación por microorganismos como Demodex folliculorum. La rosácea se clasifica en 4 variantes, que tienen un manejo terapéutico distinto, basado en el cuidado de la piel, los antiinflamatorios tópicos, los antibióticos y los retinoides tópicos o sistémicos y, en determinados casos, la terapia basada en la luz y la cirugía.
Palabras clave:
rosácea
rubefacción
Demodex folliculorum
metronidazol
ácido azelaico
tetraciclinas
retinoides
Full text is only aviable in PDF
References
[1.]
J.Q. Del Rosso.
Update on rosacea pathogenesis and correlation with medical therapeutic agents.
Cutis, 78 (2006), pp. 97-100
[2.]
K.J. Butterwick, L.S. Butterwick, A. Han.
Laser and light therapies for acne rosacea.
J Drugs Dermatol, 5 (2006), pp. 35-39
[4.]
B. Berman, D. Zell.
Subantimicrobial dose doxycycline: a unique treatment for rosacea.
Cutis, 75 (2005), pp. 19-24
[5.]
R.I. Ceilley.
Advances in the topical treatment of acne and rosacea.
J Drugs Dermatol, 3 (2004), pp. S12-S22
[6.]
R.H. Liu, M.K. Smith, S.A. Basta, E.R. Farmer.
Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials.
Arch Dermatol, 142 (2006), pp. 1047-1052
[7.]
S.A. Buechner.
Rosacea: an update.
Dermatology, 210 (2005), pp. 100-108
[8.]
S. Diamantis, H.A. Waldorf.
Rosacea: clinical presentation and pathophysiology.
J Drugs Dermatol, 5 (2006), pp. 8-12
[9.]
S. Laube, S.W. Lanigan.
Laser treatment of rosacea.
J Cosmet Dermatol, 1 (2002), pp. 188-195
[10.]
A.K. Gupta, M.M. Chaudhry.
Rosacea and its management: an overview.
J Eur Acad Dermatol Venereol, 19 (2005), pp. 273-285
[11.]
G.H. Crawford, M.T. Pelle, W.D. James, I. Rosacea.
Etiology, pathogenesis, and subtype classification.
J Am Acad Dermatol, 51 (2004), pp. 327-341
[12.]
E.J. van Zuuren, A.K. Gupta, M.D. Gover, M. Graber, S. Hollis.
Systematic review of rosacea treatments.
J Am Acad Dermatol, 56 (2007), pp. 107-115
[13.]
R. Odom.
The nosology of rosacea.
Cutis, 74 (2004), pp. 32-34
[14.]
J. Wilkin, M. Dahl, M. Detmar, L. Drake, A. Feinstein, R. Odom, et al.
Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea.
J Am Acad Dermatol, 46 (2002), pp. 584-587
[15.]
National Rosacea Society. New survey pinpoints leading factors that trigger symptoms [online]. Summer 2002. Rosacea Review. Available from: http://www.rosacea.org/rr/2002/summer/article_3.php
[16.]
J.K. Wilkin.
Why is flushing limited to a mostly facial cutaneous distribution?.
J Am Acad Dermatol, 19 (1988), pp. 309-313
[17.]
G. Murphy.
Ultraviolet light and rosacea.
Cutis, 74 (2004), pp. 32-34
[18.]
A.R. Amin, M.G. Attur, G.D. Thakker, P.D. Patel, P.R. Vyas, R.N. Patel, et al.
A novel mechanism of action of tetracyclines: effects on nitric oxide synthases.
Proc Natl Acad Sci U S A, 93 (1996), pp. 14014-14019
[19.]
M. Berg, S. Liden.
An epidemiological study of rosacea.
Acta Derm Venereol, 69 (1989), pp. 419-423
[22.]
E. Nunzi, A. Rebora, F. Hamerlinck, R.H. Cormane.
Immunopathological studies on rosacea.
Br J Dermatol, 103 (1980), pp. 543-551
[24.]
R. Marks, J.N. Harcourt-Webster.
Histopathology of rosacea.
Arch Dermatol, 100 (1969), pp. 683-691
[25.]
A.A. Ramelet, G. Perroulaz.
Rosacea: histopathologic study of 75 cases.
Ann Dermatol Venereol, 115 (1988), pp. 801-806
[26.]
S. Ayres Jr., S. Ayres 3rd.
Demodectic eruptions (demodicidosis) in the human. 30 years’ experience with 2 commonly unrecognized entities: pityriasis folliculorum (Demodex) and acne rosacea (Demodex type).
Arch Dermatol, 83 (1961), pp. 816-827
[27.]
E. Bonnar, P. Eustace, F.C. Powell.
The Demodex mite population in rosacea.
J Am Acad Dermatol, 28 (1993), pp. 443-448
[28.]
J.L. Díaz-Pérez.
Demodex mites in rosacea.
J Am Acad Dermatol, 305 (1994), pp. 812-813
[29.]
R. Marks.
Histogenesis of the inflammatory component of rosacea.
Proc R Soc Med, 66 (1973), pp. 742-745
[30.]
S. Georgala, A.C. Katoulis, G.D. Kylafis, E. Koumantaki-Mat-hioudaki, C. Georgala, K. Aroni.
Increased density of Demodex folliculorum and evidence of delayed hypersensitivity reaction in subjects with papulopustular rosacea.
J Eur Acad Dermatol Venereol, 15 (2001), pp. 441-444
[31.]
R. Hoekzema, H.J. Hulsebosch, J.D. Bos.
Demodicidosis or rosacea: what did we treat?.
Br J Dermatol, 133 (1995), pp. 294-299
[32.]
B. Amichai, M.H. Grunwald, I. Avinoach, S. Halevy.
Granulomatous rosacea associated with Demodex folliculorum.
Int J Dermatol, 31 (1992), pp. 718-719
[33.]
F. Forton, B. Seys.
Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy.
Br J Dermatol, 128 (1993), pp. 650-659
[34.]
Z. Erbagci, O. Ozgöztasi.
The significance of Demodex folliculorum density in rosacea.
Int J Dermatol, 37 (1998), pp. 421-425
[35.]
A. Rebora.
Rosacea.
J Invest Dermatol, 88 (1987), pp. 56-60
[36.]
I.K. Aronson, J.A. Rumsfield, D.P. West, J. Alexander, J.H. Fischer, F.P. Paloucek.
Evaluation of topical metronidazole gel in acne rosacea.
Drug Intell Clin Pharm, 21 (1987), pp. 346-351
[37.]
N.J. Lowe, T. Henderson, L.E. Millikan, S. Smith, K. Turk, F. Parker.
Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial.
Cutis, 43 (1989), pp. 283-286
[38.]
A. Szlachcic.
The link between Helicobacter pylori infection and rosacea.
J Eur Acad Dermatol Venereol, 16 (2002), pp. 328-333
[39.]
G. Argenziano, G. Donnarumma, M.R. Iovene, P. Arnese, M.A. Baldassarre, A. Baroni.
Incidence of anti-Helicobacter pylori and anti-CagA antibodies in rosacea patients.
Int J Dermatol, 42 (2003), pp. 601-604
[40.]
M.A. Gürer, A. Erel, D. Erbas, K. Caglar, C. Atahan.
The seroprevalence of Helicobacter pylori and nitric oxide in acne rosacea.
Int J Dermatol, 41 (2002), pp. 768-770
[41.]
A. Rebora, F. Drago, A. Picciotto.
Helicobacter pylori in patients with rosacea.
Am J Gastroenterol, 89 (1994), pp. 1603-1604
[42.]
S. Utas, O. Ozbakir, A. Turasan, C. Utas.
Helicobacter pylori eradication treatment reduces the severity of rosacea.
J Am Acad Dermatol, 40 (1999), pp. 433-435
[43.]
J.T. Bamford.
Rosacea: current thoughts on origin.
Semin Cutan Med Surg, 20 (2001), pp. 199-206
[44.]
V.K. Sharma, A. Lynn, M. Kaminski, R. Vasudeva, C.W. Howden.
A study of the prevalence of Helicobacter pylori infection and other markers of upper gastrointestinal tract disease in patients with rosacea.
Am J Gastroenterol, 93 (1998), pp. 220-222
[45.]
J.T. Bamford, R.L. Tilden, J.L. Blankush, D.E. Gangeness.
Effect of treatment of Helicobacter pylori infection on rosacea.
Arch Dermatol, 135 (1999), pp. 659-663
[46.]
A. Szlachcic, Z. Sliwowski, E. Karczewska, W. Bielanski, J. Pytko Polonczyk, S.J. Konturek.
Helicobacter pylori and its eradication in rosacea.
J Physiol Pharmacol, 50 (1999), pp. 777-786
[47.]
F.C. Powell.
Rosacea and the pilosebaceous follicle.
Cutis, 74 (2004), pp. 32-34
[48.]
D.M. Reifler, D.D. Verdier, C.L. Davy, N.D. Mostow, V.E. Wendt.
Multiple chalazia and rosacea in a patient treated with amiodarone.
Am J Ophthalmol, 103 (1987), pp. 594-595
[50.]
E.F. Sherertz.
Acneiform eruption due to “megadose” vitamins B6 and B12.
Cutis, 48 (1991), pp. 119-120
[51.]
M.T. Pelle, G.H. Crawford, W.D. James.
Rosacea: II. Therapy.
J Am Acad Dermatol, 51 (2004), pp. 499-512
[52.]
J.Q. Del Rosso.
Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants.
Cutis, 75 (2005), pp. 17-21
[53.]
T. Dirschka, H. Tronnier, R. Fölster-Holst.
Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis.
Br J Dermatol, 150 (2004), pp. 1136-1141
[54.]
National Rosacea Society. Survey finds that rosacea flare-ups are common but can be controlled [online]. Spring 1999. Rosacea Review. Available from: http://www.rosacea.org/rr/1999/spring/article_3.php
[56.]
J.B. Bikowski.
The pharmacologic therapy of rosacea: a paradigm shift in progress.
Cutis, 75 (2005), pp. 27-32
[57.]
J.Q. Del Rosso, J. Bikowski.
Topical metronidazole combination therapy in the clinical management of rosacea.
J Drugs Dermatol, 4 (2005), pp. 473-480
[59.]
S. Maddin.
A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea.
J Am Acad Dermatol, 40 (1999), pp. 961-965
[60.]
B.W. Elewski.
Azelaic acid 15% gel for treatment of rosacea.
Expert Rev Dermatol, 1 (2006), pp. 535-545
[61.]
D. Thiboutot, R. Thieroff-Ekerdt, K. Graupe.
Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies.
J Am Acad Dermatol, 48 (2003), pp. 836-845
[63.]
D.N. Sauder, R. Miller, D. Gratton, W. Danby, C. Griffiths, S.B. Phillips, et al.
The treatment of rosacea: the safety and efficacy of sodium sulfactemide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study.
J Dermatol Treat, 8 (1997), pp. 79-85
[64.]
M. Lebwohl, R.S. Medansky, C.L. Russo, R.T. Plott.
The comparative efficacy sodium sulfacetamide 10% and sulfur 5% (Sulfacet-R) lotion and metronidazole 0.75% (MetroGel) in the treatment of rosacea.
J Geriatr Dermatol, 3 (1995), pp. 183-185
[65.]
O.H. Mills Jr., A.M. Kligman.
Letter: Topically applied erythromycin in rosacea.
Arch Dermatol, 112 (1976), pp. 553-554
[66.]
J.K. Wilkin, S. DeWitt.
Treatment of rosacea: topical clindamycin versus oral tetracycline.
Int J Dermatol, 32 (1993), pp. 65-67
[67.]
A.M. Kligman, D. Dogadkina, R.M. Lavker.
Effects of topical tretinoin on non-sun-exposed protected skin of the elderly.
J Am Acad Dermatol, 29 (1993), pp. 25-33
[68.]
J.H. Saurat, L. Didierjean, E. Masgrau, P.A. Piletta, S. Jaconi, D. Chatellard-Gruaz, et al.
Topical retinaldehyde on human skin: biologic effects and tolerance.
J Invest Dermatol, 103 (1994), pp. 770-774
[69.]
J.Q. Del Rosso.
A status report on the medical management of rosacea: focus on topical therapies.
Cutis, 70 (2002), pp. 271-275
[70.]
D. Goldman.
Tacrolimus ointment for the treatment of steroidinduced rosacea: a preliminary report.
J Am Acad Dermatol, 44 (2001), pp. 995-998
[71.]
G. Webster, J.Q. Del Rosso.
Anti-inflammatory activity of tetracyclines.
Dermatol Clin, 25 (2007), pp. 133-135
[72.]
M.V. Dahl.
Rosacea subtypes: a treatment algorithm.
Cutis, 74 (2004), pp. 32-34
[73.]
M.J. Quarterman, D.W. Johnson, D.C. Abele, J.L. Lesher Jr., D.S. Hull, L.S. Davis.
Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline.
Arch Dermatol, 133 (1997), pp. 49-54
[74.]
A. Fernández-Obregón.
Oral use of azithromycin for the treatment of acne rosacea.
Arch Dermatol, 140 (2004), pp. 489-490
[75.]
C. Torresani.
Clarithromycin: a new perspective in rosacea treatment.
Int J Dermatol, 37 (1998), pp. 347-349
[76.]
K. Turjanmaa, T. Reunala.
Isotretinoin treatment of rosacea.
Acta Derm Venereol, 67 (1987), pp. 89-91
[77.]
F.G. Erdogan, P. Yurtsever, D. Aksoy, F. Eskioglu.
Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea.
Arch Dermatol, 134 (1998), pp. 884-885
[78.]
J.K. Wilkin.
Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions.
Arch Dermatol, 119 (1983), pp. 211-214
[79.]
J.K. Wilkin.
Effect of nadolol on flushing reactions in rosacea.
J Am Acad Dermatol, 20 (1989), pp. 202-205
[80.]
J.E. Bernstein, K. Soltani.
Alcohol-induced rosacea flushing blocked by naloxone.
Br J Dermatol, 107 (1982), pp. 59-61
Copyright © 2008. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
